Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles.
Drug delivery systems based on polymeric microparticles represent an interesting field of development for the treatment of several infectious diseases for humans and animals. In this work, we developed PLGA microparticles loaded with ceftiofur (PLGA-cef), a third- generation cephalosporin that is us...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4410948?pdf=render |
| _version_ | 1828785371396177920 |
|---|---|
| author | Cristian Vilos Luis A Velasquez Paula I Rodas Katherine Zepeda Soung-Jae Bong Natalia Herrera Mario Cantin Felipe Simon Luis Constandil |
| author_facet | Cristian Vilos Luis A Velasquez Paula I Rodas Katherine Zepeda Soung-Jae Bong Natalia Herrera Mario Cantin Felipe Simon Luis Constandil |
| author_sort | Cristian Vilos |
| collection | DOAJ |
| description | Drug delivery systems based on polymeric microparticles represent an interesting field of development for the treatment of several infectious diseases for humans and animals. In this work, we developed PLGA microparticles loaded with ceftiofur (PLGA-cef), a third- generation cephalosporin that is used exclusively used in animals. PLGA-cef was prepared by the double emulsion w/o/w method, and exhibited a diameter in the range of 1.5-2.2 μm, and a negative ζ potential in the range of -35 to -55 mV. The loading yield of PLGA-cef was ~7% and encapsulation efficiency was approximately 40%. The pharmacokinetic study demonstrated a sustained release profile of ceftiofur for 20 days. PLGA-cef administrated in a single dose was more effective than ceftiofur non-encapsulated in rats challenged with S. Typhimurium. The in vivo toxicological evaluation showed that PLGA-cef did not affect the blood biochemical, hematological and hemostasis parameters. Overall, the PLGA-cef showed slow in vivo release profile, high antibacterial efficacy, and low toxicity. The results obtained supports the safe application of PLGA-cef as sustained release platform in the veterinary industry. |
| first_indexed | 2024-12-11T23:50:01Z |
| format | Article |
| id | doaj.art-3b7551b90d394039a9a5dc745bc99039 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T23:50:01Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3b7551b90d394039a9a5dc745bc990392022-12-22T00:45:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012333510.1371/journal.pone.0123335Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles.Cristian VilosLuis A VelasquezPaula I RodasKatherine ZepedaSoung-Jae BongNatalia HerreraMario CantinFelipe SimonLuis ConstandilDrug delivery systems based on polymeric microparticles represent an interesting field of development for the treatment of several infectious diseases for humans and animals. In this work, we developed PLGA microparticles loaded with ceftiofur (PLGA-cef), a third- generation cephalosporin that is used exclusively used in animals. PLGA-cef was prepared by the double emulsion w/o/w method, and exhibited a diameter in the range of 1.5-2.2 μm, and a negative ζ potential in the range of -35 to -55 mV. The loading yield of PLGA-cef was ~7% and encapsulation efficiency was approximately 40%. The pharmacokinetic study demonstrated a sustained release profile of ceftiofur for 20 days. PLGA-cef administrated in a single dose was more effective than ceftiofur non-encapsulated in rats challenged with S. Typhimurium. The in vivo toxicological evaluation showed that PLGA-cef did not affect the blood biochemical, hematological and hemostasis parameters. Overall, the PLGA-cef showed slow in vivo release profile, high antibacterial efficacy, and low toxicity. The results obtained supports the safe application of PLGA-cef as sustained release platform in the veterinary industry.http://europepmc.org/articles/PMC4410948?pdf=render |
| spellingShingle | Cristian Vilos Luis A Velasquez Paula I Rodas Katherine Zepeda Soung-Jae Bong Natalia Herrera Mario Cantin Felipe Simon Luis Constandil Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. PLoS ONE |
| title | Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. |
| title_full | Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. |
| title_fullStr | Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. |
| title_full_unstemmed | Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. |
| title_short | Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles. |
| title_sort | preclinical development and in vivo efficacy of ceftiofur plga microparticles |
| url | http://europepmc.org/articles/PMC4410948?pdf=render |
| work_keys_str_mv | AT cristianvilos preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT luisavelasquez preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT paulairodas preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT katherinezepeda preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT soungjaebong preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT nataliaherrera preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT mariocantin preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT felipesimon preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles AT luisconstandil preclinicaldevelopmentandinvivoefficacyofceftiofurplgamicroparticles |